Approvability Of Arena's Lorcaserin Still Unclear
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech presented new data on its obesity drug lorcaserin, adding to analysts' question about its safety profile.
You may also be interested in...
Arena Ready For FDA To Reconsider Weight-Loss Drug Lorcaserin
Arena and Eisai expect to hear in the next week or so whether FDA will accept their answer to an October 2010 “complete response” letter and set a new action date for their novel weight loss drug.
Arena Gains Evidence To Address FDA Concerns About Lorcaserin, But More Still Needed
The biotech released some new results regarding the safety of lorcaserin as it continues to pursue FDA approval for the drug.
Arena Gains Evidence To Address FDA Concerns About Lorcaserin, But More Still Needed
The biotech released some new results regarding the safety of lorcaserin as it continues to pursue FDA approval for the drug.